ALLI (orlistat)
WEIGHT LOSS MANAGEMENT FOR OVERWEIGHT OR OBESE PATIENT (BODY MASS INDEX 27 OR GREATER)
GSK CONSUMER HE
Indication
Weight loss management for overweight or obese patient (body mass index 27 or greater)
Weight loss management for overweight or obese patients with a body mass index (BMI) of 27 kg/m² or greater represents a clinical intervention for individuals affected by excess adiposity that impairs metabolic and cardiovascular function. Read more about Weight loss management for overweight or obese patient (body mass index 27 or greater)
3 drugs 3 manufacturers
Drugs that treat it
Common Weight loss management for overweight or obese patient (body mass index 27 or greater) therapies.
ALLI (orlistat)
FAT ABSORPTION DECREASING AGENTS·WEIGHT LOSS MANAGEMENT FOR OVERWEIGHT OR OBESE PATIENT (BODY MASS INDEX 27 OR GREATER)
GSK/Haleon
ALLI (orlistat)
FAT ABSORPTION DECREASING AGENTS·WEIGHT LOSS MANAGEMENT FOR OVERWEIGHT OR OBESE PATIENT (BODY MASS INDEX 27 OR GREATER)
GSK/Haleon US
Filter & compare in the drug finder →Opens the drug finder with Weight loss management for overweight or obese patient (body mass index 27 or greater) preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonWeight loss management for overweight or obese patients with a body mass index (BMI) of 27 kg/m² or greater represents a clinical intervention for individuals affected by excess adiposity that impairs metabolic and cardiovascular function.
This clinical state involves adult populations classified as overweight (BMI 27 to 29.9 kg/m²) who typically present with at least one weight-related comorbidity—such as hypertension, dyslipidemia, or type 2 diabetes mellitus—as well as patients with clinical obesity (BMI 30 kg/m² or greater).
Pathophysiologically, the condition is driven by chronic neuroendocrine, metabolic, and energy-balance dysregulation leading to dysfunctional adipose tissue accumulation, systemic low-grade inflammation, insulin resistance, and heightened cardiometabolic risk.
- fda.gov
Weight loss management for overweight or obese patients with a body mass index (BMI) of 27 kg/m² or greater represents a clinical intervention for individuals affected by excess adiposity that impairs metabolic and cardiovascular function This clinical state involves adult populations classified as overweight (BMI 27 to 29.9 kg/m²) who typically present with at least one weight-related comorbidity—such as hypertension, dyslipidemia, or type 2 diabetes mellitus—as well as patients with clinical o...
- fda.gov
Weight loss management for overweight or obese patients with a body mass index (BMI) of 27 kg/m² or greater represents a clinical intervention for individuals affected by excess adiposity that impairs metabolic and cardiovascular function Pathophysiologically, the condition is driven by chronic neuroendocrine, metabolic, and energy-balance dysregulation leading to dysfunctional adipose tissue accumulation, systemic low-grade inflammation, insulin resistance, and heightened cardiometabolic risk
- polskieradio.pl
This clinical state involves adult populations classified as overweight (BMI 27 to 29.9 kg/m²) who typically present with at least one weight-related comorbidity—such as hypertension, dyslipidemia, or type 2 diabetes mellitus—as well as patients with clinical obesity (BMI 30 kg/m² or greater)
- nih.gov
This clinical state involves adult populations classified as overweight (BMI 27 to 29.9 kg/m²) who typically present with at least one weight-related comorbidity—such as hypertension, dyslipidemia, or type 2 diabetes mellitus—as well as patients with clinical obesity (BMI 30 kg/m² or greater)
- nih.gov
Pathophysiologically, the condition is driven by chronic neuroendocrine, metabolic, and energy-balance dysregulation leading to dysfunctional adipose tissue accumulation, systemic low-grade inflammation, insulin resistance, and heightened cardiometabolic risk
- nih.gov
Pathophysiologically, the condition is driven by chronic neuroendocrine, metabolic, and energy-balance dysregulation leading to dysfunctional adipose tissue accumulation, systemic low-grade inflammation, insulin resistance, and heightened cardiometabolic risk
Personalize your experience
Follow Weight loss management for overweight or obese patient (body mass index 27 or greater) and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.